Overcoming Thrombolytic Resistance with a Biomimetic Nanoformulation for Synergistic NETs and Fibrin Degradation in Acute Ischemic Stroke
This study presents a biomimetic nanosystem (TNK-DNaseI@ZPM) that co-encapsulates tenecteplase and DNase-I within a platelet membrane-cloaked ZIF-8 core to synergistically degrade neutrophil extracellular traps and fibrin, thereby overcoming thrombolytic resistance and enabling safer, more effective recanalization in acute ischemic stroke with large vessel occlusion.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When a major blood vessel in the brain becomes blocked, the result is a severe stroke that can cause permanent disability or death within minutes. The standard treatment involves injecting powerful clot-dissolving drugs into the bloodstream, hoping they reach the blockage in time to save the brain tissue. However, this approach often fails. The clots that cause these strokes are not just simple plugs of blood; they are complex, tangled structures reinforced by a biological meshwork released by immune cells. This meshwork acts like a stubborn scaffold, holding the clot together and shielding it from the medication. Furthermore, because the drugs travel through the entire body, they can dissolve healthy clots elsewhere, leading to dangerous bleeding in the brain. Finding a way to break down these stubborn clots quickly and safely, without harming the rest of the body, has been a persistent challenge for doctors and scientists.
Researchers have discovered that these stubborn clots contain a specific component called neutrophil extracellular traps, or NETs. These are web-like structures made of DNA and proteins, released by white blood cells to trap bacteria, but which unfortunately also trap blood cells and strengthen clots during a stroke. While a drug called deoxyribonuclease-I (DNase-I) can cut through this DNA mesh, it is too fragile to survive long in the bloodstream and cannot find the clot on its own. Another drug, tenecteplase, is excellent at dissolving the fibrin protein that makes up the clot's core, but it lacks precision and causes bleeding risks. The team of scientists behind this study, led by researchers from Jinan University and Foshan Second People's Hospital, set out to combine these two drugs into a single delivery system that could solve both problems at once.
To achieve this, the researchers engineered a tiny, biomimetic carrier. They started with a porous, cage-like structure made of zinc and organic molecules, which can hold drugs inside its hollow spaces. They loaded this cage with both the clot-dissolving tenecteplase and the DNA-cutting DNase-I. The crucial innovation was what they wrapped around this cage: a thin shell made from the membrane of a platelet, a type of blood cell responsible for clotting. By coating the drug-filled cage in a platelet membrane, the researchers created a disguise. The body's immune system sees the particle as a natural blood cell, allowing it to circulate safely. More importantly, because platelets naturally stick to damaged blood vessels and clots, this coating acts as a homing beacon, guiding the drug carrier directly to the site of the blockage.
The system also includes a built-in trigger for releasing the medicine. The environment inside a blood clot is slightly more acidic than the rest of the body. The researchers designed the cage to remain stable in normal blood but to dissolve rapidly when it encounters this acidic environment. This means the drugs stay locked inside the carrier while traveling through the bloodstream, preventing them from causing bleeding elsewhere. Once the carrier reaches the clot and senses the acidity, the cage breaks open, releasing both drugs exactly where they are needed. The DNase-I immediately begins cutting the DNA mesh that holds the clot together, while the tenecteplase attacks the fibrin structure. This dual attack is designed to break the clot apart much faster and more thoroughly than either drug could do alone.
In laboratory tests using actual clots removed from stroke patients, the new system proved highly effective. When the researchers applied the coated nanoparticles to these clots, they dissolved significantly more of the blockage than when they applied the drugs separately or without the carrier. The system worked best in the acidic conditions that mimic a real clot, releasing its payload efficiently. Crucially, the platelet membrane coating did not cause the blood cells to burst or trigger unwanted clotting, suggesting the material is safe for use in the body. The study also showed that the nanoparticles could find their way to clots in living mice much faster and more reliably than uncoated particles, accumulating at the blockage site within minutes.
When tested in mice with induced strokes, the results were even more promising. The animals treated with the new nanoparticle system saw their blood flow restored much more quickly than those treated with standard drugs. In one model, blood flow recovered to nearly 78 percent of normal levels within twenty minutes, a speed that surpassed the combination of the two drugs given separately. The treated mice also suffered less brain damage, with smaller areas of dead tissue, and showed better recovery of movement and function. Perhaps most importantly for patient safety, the new system caused significantly less bleeding in the brain compared to the standard drug treatment. Because the drugs were released only at the clot site, the rest of the body's blood vessels remained intact, reducing the risk of hemorrhage.
The researchers confirmed that the treatment worked by breaking down the specific DNA meshwork inside the clots. In the brains of the treated mice, the levels of these stubborn DNA structures were lower, indicating that the DNase-I had successfully cut through the scaffold. This allowed the tenecteplase to reach and dissolve the fibrin more effectively. The study suggests that this approach of using a platelet-mimicking carrier to deliver a dual-drug payload offers a new way to overcome the resistance that often makes current stroke treatments fail. While the research is still in the experimental stage and has not yet been tested in humans, the findings provide a strong foundation for a future therapy that could dissolve dangerous clots quickly and safely, potentially saving lives and reducing disability for millions of stroke patients.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.